Cannabidiol (CBD) in the Therapeutics Industry

Drug Enforcement and Policy Center, No. 10, August 2019

Ohio State Public Law Working Paper No. 495

9 Pages Posted: 20 Aug 2019

See all articles by Sara Goots Blair

Sara Goots Blair

Ohio State University (OSU) - Michael E. Moritz College of Law

Date Written: August 19, 2019

Abstract

Use of Cannabidiol (CBD) in the therapeutics industry has become increasingly popular in the last few years. CBD rode into public consciousness on the coattails of three booming consumer trends: the herbal supplement industry, the anxiety economy, and the growing legitimate cannabis industry. However, many uncertainties remain about the legality, safety, and quality of CBD. The passage of the 2018 Farm Bill legalized hemp production throughout the US, thereby removing hemp-derived CBD from Center for Disease Control and Prevention (CDC)-regulation. However, the U.S. Food and Drug Administration (FDA) still stakes a claim on regulating dietary supplements and food additives containing CBD. The sudden legality of CBD, coupled with uncertainty as to its safety, quality, and effectiveness, means it is imperative for states to support research and impose sufficient regulatory oversight over CBD-infused products.

Keywords: CBD, hemp, cannabidiol, regulation, FDA, oversight

Suggested Citation

Blair, Sara Goots, Cannabidiol (CBD) in the Therapeutics Industry (August 19, 2019). Drug Enforcement and Policy Center, No. 10, August 2019; Ohio State Public Law Working Paper No. 495. Available at SSRN: https://ssrn.com/abstract=3439383 or http://dx.doi.org/10.2139/ssrn.3439383

Sara Goots Blair (Contact Author)

Ohio State University (OSU) - Michael E. Moritz College of Law ( email )

55 West 12th Avenue
Columbus, OH 43210
United States

Here is the Coronavirus
related research on SSRN

Paper statistics

Downloads
5
Abstract Views
343
PlumX Metrics